Vivanza Biosciences revenue falls 79%, profit down 76%

Vivanza Biosciences Limited reported consolidated revenue from operations of Rs 11.4128 crore for the quarter ended 30 September 2026, down 79% from Rs 55.3578 crore a year earlier, while profit for the period fell 76% to Rs 13.64 lakh from Rs 56.29 lakh. The Board approved the unaudited results on 6 November 2026.

Why did Vivanza Biosciences' September-quarter profit fall?

Vivanza Biosciences' September-quarter profit fell as revenue from operations contracted by Rs 43.945 crore year on year, while total expenses fell by Rs 43.5808 crore. Revenue from operations was Rs 11.4128 crore in the quarter ended 30 September 2026, compared with Rs 55.3578 crore in the corresponding 2025 quarter. Profit before tax was Rs 16.86 lakh, down from Rs 56.29 lakh a year earlier.

Total income, which includes other income, was Rs 11.3902 crore in the September 2026 quarter, compared with Rs 55.3653 crore in September 2025. Other income was negative Rs 2.26 lakh in the latest quarter, against Rs 76,000 a year earlier. The results statement does not report an exceptional-item amount for either September quarter, so reported profit before tax was unchanged by exceptional items in both periods.

Tax expense of Rs 3.22 lakh in the September 2026 quarter comprised Rs 3.20 lakh of current tax and Rs 2,000 of deferred tax. This reduced profit for the period to Rs 13.64 lakh, compared with Rs 56.29 lakh in the prior-year quarter, when the statement shows no tax expense. Basic and diluted earnings per share, not annualised, were Rs 0.03, against Rs 0.14 in September 2025.

How did Vivanza Biosciences' revenue and costs change?

Vivanza Biosciences recorded total expenses of Rs 11.2216 crore in the September 2026 quarter, versus Rs 54.8024 crore in the September 2025 quarter. The decline in expenses was broadly similar in rupee terms to the reduction in revenue, but the difference between total income and expenses narrowed to Rs 16.86 lakh from Rs 56.29 lakh. The company identifies pharmaceuticals-related activities as its sole operating segment.

Cost of materials consumed declined to Rs 10.4689 crore in the September 2026 quarter from Rs 55.9944 crore a year earlier, and rose from Rs 9.4731 crore in the June 2026 quarter. The latest quarter also included Rs 42.76 lakh from the increase or decrease in inventories of finished goods, work in progress and stock-in-trade, compared with negative Rs 155.71 lakh a year earlier.

Employee-benefit expense was Rs 10.43 lakh in the September quarter, down from Rs 24.82 lakh in September 2025 but above Rs 9.56 lakh in June 2026. Finance cost was Rs 4.47 lakh, compared with Rs 10.62 lakh in the preceding quarter and Rs 4.71 lakh a year earlier. Other expenses rose to Rs 17.08 lakh from Rs 4.81 lakh in June, while depreciation and amortisation was Rs 54,000 in both 2026 quarters.

What do Vivanza Biosciences' first-half results show?

Vivanza Biosciences reported revenue from operations of Rs 20.7025 crore for the six months ended 30 September 2026, down from Rs 64.297 crore in the six months ended 30 September 2025. Total income was Rs 21.0527 crore, compared with Rs 64.322 crore in the corresponding prior-year period. Profit for the period declined to Rs 28.31 lakh from Rs 64.98 lakh.

Total expenses in the first half were Rs 20.7017 crore, compared with Rs 63.6722 crore in the year-earlier half, producing profit before tax of Rs 35.10 lakh versus Rs 64.98 lakh. Tax expense was Rs 6.79 lakh, consisting of Rs 6.75 lakh of current tax and Rs 4,000 of deferred tax. First-half basic and diluted earnings per share, not annualised, were Rs 0.07, compared with Rs 0.16 a year earlier.

The quarter-on-quarter comparison differed from the year-on-year movement. Revenue from operations increased by Rs 2.1231 crore from Rs 9.2897 crore in the June 2026 quarter to Rs 11.4128 crore in September. However, profit for the period decreased by Rs 1.03 lakh from Rs 14.67 lakh, while profit before tax fell from Rs 18.24 lakh to Rs 16.86 lakh.

The September quarter supplied Rs 11.3902 crore of the first half's Rs 21.0527 crore total income. June-quarter total income was Rs 9.6625 crore, including other income of Rs 37.28 lakh, whereas September-quarter other income was negative Rs 2.26 lakh. The company has not provided a separate segmental breakdown because it reports only pharmaceuticals-related activities.

What changed in Vivanza Biosciences' balance sheet and cash flow?

Vivanza Biosciences' consolidated total assets rose to Rs 28.9793 crore at 30 September 2026 from Rs 22.0874 crore at 31 March 2026. Trade receivables increased to Rs 19.9674 crore from Rs 12.3833 crore, while inventories declined to Rs 3.3715 crore from Rs 3.5507 crore. Cash and cash equivalents declined to Rs 5.18 lakh from Rs 6.53 lakh.

Total equity increased to Rs 4.6415 crore at 30 September from Rs 4.3585 crore at the March 2026 year-end, as other equity rose to Rs 64.15 lakh from Rs 35.85 lakh. Non-current borrowings increased to Rs 2.7691 crore from Rs 87.72 lakh, while current borrowings declined to Rs 7.2432 crore from Rs 9.3146 crore. Trade payables rose to Rs 12.8422 crore from Rs 7.194 crore.

Consolidated net cash flow from operating activities was an outflow of Rs 2.447 crore for the six months ended 30 September 2026. This followed an operating cash outflow of Rs 1.2599 crore for the full year ended 31 March 2026, so the filing's two reported cash-flow periods are not like-for-like. During the 2026 half-year, trade receivables absorbed Rs 7.5841 crore of cash, partly offset by a Rs 5.6482 crore increase in trade payables.

Investing activities generated Rs 69.25 lakh in the six months ended 30 September 2026, including Rs 1.6064 crore from the sale of property, plant and equipment and Rs 91.20 lakh spent on investments. Financing activities generated Rs 1.741 crore, including Rs 1.8919 crore from borrowings and Rs 15.09 lakh of interest expense. These movements resulted in a Rs 1.35 lakh decrease in cash and cash equivalents over the half-year.

Conclusion

Vivanza Biosciences' September 2026 results show that the year-on-year decline in consolidated revenue from operations, to Rs 11.4128 crore from Rs 55.3578 crore, coincided with lower profit of Rs 13.64 lakh. The six-month figures point in the same direction, with revenue from operations of Rs 20.7025 crore and profit of Rs 28.31 lakh, compared with Rs 64.297 crore and Rs 64.98 lakh respectively a year earlier.

The next quarterly results will show whether revenue from operations continues to recover from the Rs 9.2897 crore reported in June 2026 to Rs 11.4128 crore in September. The filing also leaves receivables, which rose to Rs 19.9674 crore at 30 September 2026, and the first-half operating cash outflow of Rs 2.447 crore as disclosed balance-sheet and cash-flow items to watch.